.......and even further, SBN once FDA approval is attained will most certainly enjoy a first mover advantage and probably about a 6 month window on current competitors who will then need to file for FDA approval in order to stay in the game. Vintage covered the scenario really well.
It is worth noting that SBN was sited by the FDA Agency, a stroke of luck in fact but now provides Sun Biomedical with a mammoth chance to gain some serious traction. Once achieved, the skill and ability of the SBN management to implement and execute a successful global multi-channel distribution strategy enabling the leveraging of the technology will eventually be the acid test for future success or failure. With such an excellent and superior product feeding an insatiable market in a myriad of sectors including workplace, schools, sport, roadside testing, the inherent risk here must surely be the inability of SBN management to gain the required traction given the window of opportunity that will soon present itself. I am betting they will but the caveat must be that many have failed before under similar circumstances!
SBN Price at posting:
0.0¢ Sentiment: ST Buy Disclosure: Held
